TP Therapeutics公司，一家专注于解决肿瘤耐药性问题的临床阶段生物制药公司，今天宣布该公司C轮融资筹集了4500万美元。 该轮由礼来亚洲基金（Lilly Asia Ventures），奥博资本（OrbiMed Advisors）和S.R. One这三家著名风投公司领投，现有投资者Cormorant Asset Management和SV Tech Venture参投。 成功融资之际，OrbiMed的Carl L. Gordon博士，礼来亚洲基金的的Hongbo Lu博士，S.R. One的Simeon J. George医学博士加入TP Therapeutics的公司董事会。详情请见以下新闻稿。
TP Therapeutics Closes $45M Series C Financing
SAN DIEGO--(BUSINESS WIRE)--TP Therapeutics, Inc., a clinical-stage biopharmaceutical company focusing on addressing oncology drug resistance, announced today that the company raised $45 million in a Series C financing round. The round was co-led by Lilly Asia Ventures (LAV), OrbiMed Advisors, LLC, and S.R. One, Limited, and joined by existing investors Cormorant Asset Management and SV Tech Ventures. In conjunction with the financing, Carl L. Gordon, Ph.D., CFA, General Partner at OrbiMed, Hongbo Lu, Ph.D., Partner at LAV, and Simeon J. George, M.D., Partner at S.R. One, joined the company's Board of Directors.
Proceeds from the financing will be used to fund the continued development of the company's lead program, TPX-0005, for treatment of naïve and resistant patients with ALK, ROS1 or NTRK abnormal genes. The proceeds will also be used to fund the advancement of several pre-clinical pipeline projects.
"We believe TPX-0005 has the potential to comprehensively address the drug resistance issues associated with acquired resistance mutations from targeting the ALK, ROS1, and NTRK family, and the bypass and EMT mechanisms. With bypass and EMT as common resistance mechanisms in targeted therapies, TPX-0005 has the potential to address drug resistance observed in other therapeutic targets, such as EGFR, via combination therapies,” said Dr. J. Jean Cui, founder and Chief Scientific Officer. "We are very delighted to work with OrbiMed, LAV, and S.R. One in building TP Therapeutics going forward, and to have Carl, Hongbo, and Simeon join the Board of Directors," added Dr. Y. Peter Li, Chairman, President and CEO of TP Therapeutics.
"We are pleased to partner with TP Therapeutics and support their important work in creating new drugs and new hope for the numerous patients whose cancers have become resistant to initial protein kinase inhibitor drugs," commented Dr. Carl Gordon, OrbiMed.
“We are privileged to have an opportunity to syndicate such an exceptional investor group for this round of financing. We look forward to supporting the TP Therapeutics scientists and management team to bring new therapies to cancer patients around the world,” remarked Dr. Hongbo Lu, LAV.
About TP Therapeutics, Inc.
TP Therapeutics, Inc. (TP) is a clinical-stage structure-based drug design company founded in October 2013 by Dr. J. Jean Cui, the lead inventor of Pfizer’s oncology drug crizotinib. TP Team is focusing on the design and development of novel chemical identities for established oncogene drivers with high incidence of secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity. TP’s leading project TPX-0005 is in clinical development (TRIDENT-1, NCT03093116).
About OrbiMed Advisors, LLC
OrbiMed is a leading investment firm dedicated exclusively to the healthcare sector, with over US $13 billion in assets under management. OrbiMed invests globally across the spectrum of healthcare companies, from venture capital start-ups to large multinational companies. OrbiMed's team of more than 90 employees manages a series of private equity funds, public equity funds, royalty/debt funds and other investment vehicles. OrbiMed maintains its headquarters in New York City, with additional offices in San Francisco, Mumbai, Shanghai, and Herzliya.
About Lilly Asia Ventures (LAV)
Lilly Asia Ventures (LAV), founded in 2008 and headquartered in Shanghai, is a life sciences and healthcare sector focused investment firm, focusing predominantly on biopharmaceutical, med tech and diagnostics investments in Asia, particularly in China. As a leading biomedical venture fund, LAV provides capital, industry expertise, and global resources to its portfolio companies to accelerate their growth.
About S.R. One, Limited
S.R. One, Limited is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. We have a team of investment professionals, located in the US and UK. As a Team, our experience spans basic science, industry and the market. We take an active role in our portfolio companies and work with management teams and our fellow venture investors to create significant value. Celebrating its 30th anniversary in 2015, S.R. One has invested $1B in more than 170 companies, and its current portfolio includes ~45 private and public companies.
Contacts
TP Therapeutics, Inc.
Y. Peter Li, Ph.D., M.B.A.
858-926-5251
peter.li@tptherapeutics.com
（来源：TP Therapeutics）
欢迎欣赏紫薯的原创文章！
早中期非小细胞肺癌靶向、免疫疗法最新进展 （2017-05-24）
晚期肺癌怎么“诊+治”，看MSKCC的临床试验总结 （2017-05-02）
原创 | 肺癌靶向药物最新进展，耐药机制及对策 （2017-04-10）
非阿片类镇痛潜力靶点：从CIPA发现的NGF-TRKA通路 （2017-03-06）
液体活检市场前景浅析：千亿美元的大金矿还是画大饼，白日梦？（2017-02-26）
厉害了，肿瘤液体活检！cfDNA伴随诊断成功案例分析 （2017-02-12）
细胞凋亡靶向小分子药物研发和应用前景浅析 | 附我心目中的细胞凋亡科研大牛榜 （2017-01-27）
【重磅原创】非小细胞肺癌ALK耐药分子机制最新动态（2016-08-01）
【重磅原创】白血病靶向药物最新进展（2016-07-29）
【原创】最靠谱的HPV肿瘤疫苗为什么在美国推广不力，在国内港游却热爆？（2016-07-03）
【原创文章】肿瘤免疫疗法那么贵，中间停药获益会持续吗？（2016-06-25）
【重磅原创 独家首发】肺癌靶向药物最新进展（2016-06-12）
【原创】大牛Stephen Fesik的下一个目标盯上了谁？Mcl-1 靶向药有潜力成为下一个重磅吗？（2016-06-07）
-
【重磅原创】艾伯维与罗氏联合开发的靶向药Venetoclax究竟好在哪？浅议Bcl-2靶向药Venetoclax的潜在优越性（2016-05-23）
药时代，新时代！我们共创精彩的未来！
